Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
56 hedge funds and large institutions have $23.8M invested in Merrimack Pharmaceuticals, Inc. in 2018 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 13 increasing their positions, 22 reducing their positions, and 14 closing their positions.
11% less funds holding
Funds holding: 63 → 56 (-7)
29% less capital invested
Capital invested by funds: $33.6M → $23.8M (-$9.83M)
41% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 22
43% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 14
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $23K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
2L
22NW LP
Seattle,
Washington
|
+$3.3M |
| 2 |
NM
Newtyn Management
New York
|
+$942K |
| 3 |
WSL
Western Standard LLC
Los Angeles,
California
|
+$663K |
| 4 |
JGC
J. Goldman & Co
New York
|
+$230K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$207K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$2.96M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$1.71M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.45M |
| 4 |
Millennium Management
New York
|
-$465K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$337K |
MACK Hedge Fund Activity: Q4 2018 in Review
56 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q4 2018, worth a combined $23.8M — down 29% from $33.6M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of MACK and 8 opened new positions — a net loss of 6 holders — while 22 trimmed existing stakes and 13 added.
The largest buyer was 22NW LP, opening a new position worth an estimated $3.3M. The largest seller was Rubric Capital Management (New York), exiting entirely with an estimated $2.96M sold.
- 56 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q4 2018, down from 63 in Q3 2018.
- Funds reported $23.8M of Merrimack Pharmaceuticals, Inc. stock for Q4 2018, down 29% quarter-over-quarter.
- 8 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q4 2018 and 14 closed out, a net change of -6 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q4 2018 was 22NW LP, an estimated $3.3M added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q4 2018 was Rubric Capital Management (New York), an estimated $2.96M sold.
Based on aggregated 13F filings for Q4 2018.